Media

Clinical Insights: July 19, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Beyfortus™ (nirsevimab-alip) Injection – New Drug Approval – July 17, 2023 – The U.S. Food and Drug Administration approved Beyfortus™ (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…

Read More...

Clinical Insights: June 28, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Litfulo™ (ritlecitinib) – New Drug Approval – June 23, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib), a…

Read More...

Clinical Insights: June 7, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Abrysvo™ (respiratory syncytial virus vaccine) Injection – New Drug Approval – May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has…

Read More...

Clinical Insights: June 1, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Inpefa™ (sotagliflozin) – New Drug Approval ­– May 26, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the U.S. Food and Drug Administration (FDA) has approved Inpefa™ (sotagliflozin),…

Read More...

Clinical Insights: May 10, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Mydcombi™ (phenylephrine hydrochloride and tropicamide) Ophthalmic Spray – New Drug Approval ­– May 5, 2023 –  Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for…

Read More...

Clinical Insights: April 5, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval  Padcev®(enfortumab vedotin-ejfv) and Keytruda®(pembrolizumab) for Injection – New Label Expansion – April 3, 2023 –  The Food and Drug Administration granted accelerated approval…

Read More...

Clinical Insights: March 29, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Joenja® (leniolisib) Tablets – New Drug Approval ­– March 24, 2023 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adult…

Read More...

Clinical Insights: March 22, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tafinlar® (dabrafenib) – New Label Expansion – March 16, 2023 – The Food and Drug Administration approved dabrafenib (Tafinlar®, Novartis) with trametinib (Mekinist®,…

Read More...

Clinical Insights: March 15, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Daybue™ (trofinetide) Oral Solution – New Drug Approval – March 10, 2023 – Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Daybue™ (trofinetide)…

Read More...

Clinical Insights: March 8, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Skyclarys™ (omaveloxolone) Capsules – New Orphan Drug Approval – February 28, 2023 – FDA has approved Skyclarys™ (omaveloxolone) as the first treatment for Friedreich’s ataxia, a rare, inherited, degenerative…

Read More...

Clinical Insights: March 1, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage February 27, 2023 Rocuronium Bromide Injection (Currently in Shortage) February 24, 2023 Ethacrynate Sodium Injection (Discontinuation) Rocuronium…

Read More...

Clinical Insights: February 22, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Filspari™ (sparsentan) Tablets – New Drug Approval – February 17, 2023 – Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to…

Read More...